Literature DB >> 30458979

Development and translation of novel therapeutics targeting tumor-associated macrophages.

David Kosoff1, Joshua M Lang2.   

Abstract

Tumor-associated macrophages (TAMs) regulate an array of tumor functions and have critical roles in both the progression and the eradication of cancer. Numerous therapies targeting TAMs are under development in cancer and many have demonstrated success at the preclinical and clinical levels. Most of these therapies fall within 3 main categories: systemic depletion of TAMs, inhibition of TAM recruitment and polarization, and promoting the antitumor functions of TAMs. In this article, the rationale behind these various therapies and approaches is reviewed along with supporting preclinical and clinical data.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer; Therapy development; Tumor microenvironment; Tumor-associated macrophages

Mesh:

Year:  2018        PMID: 30458979      PMCID: PMC6525088          DOI: 10.1016/j.urolonc.2018.10.010

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  47 in total

1.  The chemokine CCL2 increases prostate tumor growth and bone metastasis through macrophage and osteoclast recruitment.

Authors:  Kosuke Mizutani; Sudha Sud; Natalie A McGregor; Gari Martinovski; Brandon T Rice; Matthew J Craig; Zachary S Varsos; Hernan Roca; Kenneth J Pienta
Journal:  Neoplasia       Date:  2009-11       Impact factor: 5.715

2.  Emodin suppresses pulmonary metastasis of breast cancer accompanied with decreased macrophage recruitment and M2 polarization in the lungs.

Authors:  Xuemei Jia; Fang Yu; Junfeng Wang; Stephen Iwanowycz; Fatma Saaoud; Yuzhen Wang; Jun Hu; Qian Wang; Daping Fan
Journal:  Breast Cancer Res Treat       Date:  2014-10-14       Impact factor: 4.872

3.  Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells.

Authors:  Giovanni Germano; Roberta Frapolli; Matteo Simone; Michele Tavecchio; Eugenio Erba; Samantha Pesce; Fabio Pasqualini; Federica Grosso; Roberta Sanfilippo; Paolo G Casali; Alessandro Gronchi; Emanuela Virdis; Eva Tarantino; Silvana Pilotti; Angela Greco; Manuela Nebuloni; Carlos Maria Galmarini; Juan Carlos Tercero; Alberto Mantovani; Maurizio D'Incalci; Paola Allavena
Journal:  Cancer Res       Date:  2010-03-09       Impact factor: 12.701

4.  Anti-tumor and immunomodulatory activity of intraperitoneal IFN-gamma in ovarian carcinoma patients with minimal residual tumor after chemotherapy.

Authors:  N Colombo; F Peccatori; C Paganin; S Bini; M Brandely; C Mangioni; A Mantovani; P Allavena
Journal:  Int J Cancer       Date:  1992-04-22       Impact factor: 7.396

5.  CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans.

Authors:  Gregory L Beatty; Elena G Chiorean; Matthew P Fishman; Babak Saboury; Ursina R Teitelbaum; Weijing Sun; Richard D Huhn; Wenru Song; Dongguang Li; Leslie L Sharp; Drew A Torigian; Peter J O'Dwyer; Robert H Vonderheide
Journal:  Science       Date:  2011-03-25       Impact factor: 47.728

6.  Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness.

Authors:  Elisa Giannoni; Francesca Bianchini; Lorenzo Masieri; Sergio Serni; Eugenio Torre; Lido Calorini; Paola Chiarugi
Journal:  Cancer Res       Date:  2010-08-10       Impact factor: 12.701

7.  CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration.

Authors:  Robert D Loberg; Chi Ying; Matt Craig; Li Yan; Linda A Snyder; Kenneth J Pienta
Journal:  Neoplasia       Date:  2007-07       Impact factor: 5.715

8.  CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages.

Authors:  David G DeNardo; Jairo B Barreto; Pauline Andreu; Lesley Vasquez; David Tawfik; Nikita Kolhatkar; Lisa M Coussens
Journal:  Cancer Cell       Date:  2009-08-04       Impact factor: 31.743

Review 9.  Tumour-associated macrophages as treatment targets in oncology.

Authors:  Alberto Mantovani; Federica Marchesi; Alberto Malesci; Luigi Laghi; Paola Allavena
Journal:  Nat Rev Clin Oncol       Date:  2017-01-24       Impact factor: 66.675

10.  CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.

Authors:  Yu Zhu; Brett L Knolhoff; Melissa A Meyer; Timothy M Nywening; Brian L West; Jingqin Luo; Andrea Wang-Gillam; S Peter Goedegebuure; David C Linehan; David G DeNardo
Journal:  Cancer Res       Date:  2014-07-31       Impact factor: 12.701

View more
  3 in total

Review 1.  Prostate cancer research: The next generation; report from the 2019 Coffey-Holden Prostate Cancer Academy Meeting.

Authors:  Andrea K Miyahira; Adam Sharp; Leigh Ellis; Jennifer Jones; Salma Kaochar; H Benjamin Larman; David A Quigley; Huihui Ye; Jonathan W Simons; Kenneth J Pienta; Howard R Soule
Journal:  Prostate       Date:  2019-12-11       Impact factor: 4.104

Review 2.  Nanoparticles Targeting Macrophages as Potential Clinical Therapeutic Agents Against Cancer and Inflammation.

Authors:  Guorong Hu; Mengfei Guo; Juanjuan Xu; Feng Wu; Jinshuo Fan; Qi Huang; Guanghai Yang; Zhilei Lv; Xuan Wang; Yang Jin
Journal:  Front Immunol       Date:  2019-08-21       Impact factor: 7.561

3.  Echinococcus multilocularis drives the polarization of macrophages by regulating the RhoA-MAPK signaling pathway and thus affects liver fibrosis.

Authors:  Shigui Chong; Gen Chen; Zhisheng Dang; Fuqiu Niu; Linghui Zhang; Hui Ma; Yumin Zhao
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.